December 12th, 2011
Large Analysis Confirms Safety of ADHD Medications
Larry Husten, PHD
The cardiovascular safety of ADHD (attention-deficit/hyperactivity disorder) drugs has been uncertain. Now a large new study published online in JAMA provides reassurance that the drugs are safe. Laurel Habel and colleagues analyzed data from more than 440,000 adults, including 150,359 users of ADHD medications, and matched nonusers and found “no evidence of an increased risk of […]
November 1st, 2011
No Increased Risk for CV Events with ADHD Drugs, Large Study Finds
Larry Husten, PHD
A large new study may help lay to rest concerns that the widely prescribed ADHD drugs may increase the risk for cardiovascular (CV) events. In a study funded by the Agency for Healthcare Research and Quality and the FDA and published in the New England Journal of Medicine, William Cooper and colleagues analyzed data from 1.2 million […]
NEJM Journal Watch — Recent Cardiology Articles- Cardiovascular Outcomes of Tirzepatide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
- To Lower Stroke Risk in Patients Undergoing Atrial Fibrillation Ablation, Is a Device or a Medication Better?
- Intensive vs. Standard Blood Pressure Lowering in Patients with Diabetes
- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long Is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction